Biopharmaceutical firms in Europe raised 44 per cent less in venture capital between July and September this year than during the same period last year, figures from Dow Jones VentureSource have shown.
Some €163 million was invested in 29 biopharma projects according to the latest data, compared with €292m during the same period last year. This follows an overall decline since 2005 (see graph via link to PDF below).
This article on Research Professional News is only available to Research Professional or Pivot-RP users.
Research Professional users can log in and view the article via this link
Pivot-RP users can log in and view the article via this link.